去势抵抗型前列腺癌的治疗进展
发布时间：2018-09-11 06:03
【摘要】：前列腺癌是在老年男性中发病率较高恶性肿瘤。在欧洲个别国家，前列腺癌早已超过肺癌的发病率，位居为首位。而在我国，由于现在人们生活习性方式、饮食习性的不断变化和老年男性构成比越来越大，前列腺癌的发病率也出现朝不断上升的势头，并且发病年龄逐渐呈现年轻化发展。目前前列腺癌的主要治疗方式为前列腺根治术、内分泌治疗、化疗、放疗。但是多数患者诊断时已经多处于晚期，失去了手术根治机会，并且绝大多数患者在内分泌治疗过程当中，初始阶段治疗效果可，但是几乎所有最初对内分泌治疗敏感的患者在经过一段时间后都可能发展成为CRPC。如果发展成为CRPC，势必会给临床医生在治疗放疗带来棘手的问题，，而且如治疗效果不佳，严重时患者有生命危险可能。临床上CRPC是前列腺癌死亡的重要原因，近年来美国FDA批准了多种新药用于CRPC的治疗，如卡巴他赛、新型雄激素合成抑制剂（阿比特龙，TAK-700）、雄激素受体拮抗剂（MDV3100）、狄诺塞麦（Denosumab）以及新的免疫疗法（Sipuleucel-T）等，还有一些正在进行临床试验的新药，如Ixabepilone、普利姆玛（lpilimumab）、阿曲生坦(Atrasentan， Xinlay)等等。
[Abstract]:Prostate cancer is associated with a higher incidence of malignant tumors in older men. In individual European countries, prostate cancer has long exceeded the incidence of lung cancer, ranking first. But in our country, because of the living habits of people, the changing of diet habits and the increasing proportion of the old men, the incidence of prostate cancer is also rising, and the age of the disease is developing younger. At present, prostate cancer is mainly treated by radical prostatectomy, endocrine therapy, chemotherapy, radiotherapy. However, most of the patients have been in the late stage of diagnosis, they have lost the opportunity of radical surgery, and most of the patients have been treated effectively in the initial stage of endocrine therapy. But almost all patients who were initially sensitive to endocrine therapy could develop CRPC. over time. If it develops into CRPC, it will inevitably bring the clinician a difficult problem in the treatment of radiotherapy, and if the treatment effect is not good, the patient may be at risk of life in severe cases. Clinically, CRPC is an important cause of death from prostate cancer. In recent years, FDA in the United States has approved a variety of new drugs for the treatment of CRPC, such as carbatin. New androgen synthesis inhibitors (Abidrol TAK-700) androgen receptor antagonists (MDV3100) Dinosemer (Denosumab) and new immunotherapy (Sipuleucel-T) as well as some new drugs in clinical trials such as Ixabepilone, Plimma (lpilimumab), Atrixantan (Atrasentan, Xinlay) and so on.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.25
[Abstract]:Prostate cancer is associated with a higher incidence of malignant tumors in older men. In individual European countries, prostate cancer has long exceeded the incidence of lung cancer, ranking first. But in our country, because of the living habits of people, the changing of diet habits and the increasing proportion of the old men, the incidence of prostate cancer is also rising, and the age of the disease is developing younger. At present, prostate cancer is mainly treated by radical prostatectomy, endocrine therapy, chemotherapy, radiotherapy. However, most of the patients have been in the late stage of diagnosis, they have lost the opportunity of radical surgery, and most of the patients have been treated effectively in the initial stage of endocrine therapy. But almost all patients who were initially sensitive to endocrine therapy could develop CRPC. over time. If it develops into CRPC, it will inevitably bring the clinician a difficult problem in the treatment of radiotherapy, and if the treatment effect is not good, the patient may be at risk of life in severe cases. Clinically, CRPC is an important cause of death from prostate cancer. In recent years, FDA in the United States has approved a variety of new drugs for the treatment of CRPC, such as carbatin. New androgen synthesis inhibitors (Abidrol TAK-700) androgen receptor antagonists (MDV3100) Dinosemer (Denosumab) and new immunotherapy (Sipuleucel-T) as well as some new drugs in clinical trials such as Ixabepilone, Plimma (lpilimumab), Atrixantan (Atrasentan, Xinlay) and so on.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.25
【参考文献】
相关期刊论文 前3条
1 于永刚;;前列腺癌的放射治疗[J];临床外科杂志;2006年02期
2 张晓智;黄珊;;要重视放射治疗在前列腺癌治疗中的作用[J];现代泌尿外科杂志;2011年03期
3 喻彬;须霆;邹青;杨尔p
本文编号：2235794
本文链接：https://www.wllwen.com/yixuelunwen/mjlw/2235794.html
最近更新
教材专著
